Found: 16
Select item for more details and to access through your institution.
Role of Cytokines and Other Soluble Factors in Tumor Development: Rationale for New Therapeutic Strategies.
- Published in:
- Cells (2073-4409), 2023, v. 12, n. 21, p. 2532, doi. 10.3390/cells12212532
- By:
- Publication type:
- Article
Prostaglandin E2 transactivates the colony-stimulating factor-1 receptor and synergizes with colony-stimulating factor-1 in the induction of macrophage migration via the mitogen-activated protein kinase ERK1/2.
- Published in:
- FASEB Journal, 2015, v. 29, n. 6, p. 2545, doi. 10.1096/fj.14-258939
- By:
- Publication type:
- Article
Simultaneous Combination of the CDK4/6 Inhibitor Palbociclib With Regorafenib Induces Enhanced Anti-tumor Effects in Hepatocarcinoma Cell Lines.
- Published in:
- Frontiers in Oncology, 2020, v. 10, p. N.PAG, doi. 10.3389/fonc.2020.563249
- By:
- Publication type:
- Article
The anti-tumor efficacy of CDK4/6 inhibition is enhanced by the combination with PI3K/AKT/mTOR inhibitors through impairment of glucose metabolism in TNBC cells.
- Published in:
- Journal of Experimental & Clinical Cancer Research (17569966), 2018, v. 37, p. 1, doi. 10.1186/s13046-018-0741-3
- By:
- Publication type:
- Article
Trastuzumab emtansine delays and overcomes resistance to the third-generation EGFR-TKI osimertinib in NSCLC EGFR mutated cell lines.
- Published in:
- Journal of Experimental & Clinical Cancer Research (17569966), 2017, p. 1, doi. 10.1186/s13046-017-0653-7
- By:
- Publication type:
- Article
Dual Inhibition of CDK4/6 and PI3K/AKT/mTOR Signaling Impairs Energy Metabolism in MPM Cancer Cells.
- Published in:
- International Journal of Molecular Sciences, 2020, v. 21, n. 14, p. 5165, doi. 10.3390/ijms21145165
- By:
- Publication type:
- Article
Pre-treatment with the CDK4/6 inhibitor palbociclib improves the efficacy of paclitaxel in TNBC cells.
- Published in:
- Scientific Reports, 2019, v. 9, n. 1, p. N.PAG, doi. 10.1038/s41598-019-49484-4
- By:
- Publication type:
- Article
CDK4/6 inhibitors improve the anti-tumor efficacy of lenvatinib in hepatocarcinoma cells.
- Published in:
- Frontiers in Oncology, 2022, v. 12, p. 1, doi. 10.3389/fonc.2022.942341
- By:
- Publication type:
- Article
CDK4/6 Inhibition Enhances the Efficacy of Standard Chemotherapy Treatment in Malignant Pleural Mesothelioma Cells.
- Published in:
- Cancers, 2022, v. 14, n. 23, p. 5925, doi. 10.3390/cancers14235925
- By:
- Publication type:
- Article
Efficacy of the CDK4/6 Dual Inhibitor Abemaciclib in EGFR-Mutated NSCLC Cell Lines with Different Resistance Mechanisms to Osimertinib.
- Published in:
- Cancers, 2021, v. 13, n. 1, p. 6, doi. 10.3390/cancers13010006
- By:
- Publication type:
- Article
Pemetrexed Enhances Membrane PD-L1 Expression and Potentiates T Cell-Mediated Cytotoxicity by Anti-PD-L1 Antibody Therapy in Non-Small-Cell Lung Cancer.
- Published in:
- Cancers, 2020, v. 12, n. 3, p. 666, doi. 10.3390/cancers12030666
- By:
- Publication type:
- Article
PTEN Alterations as a Potential Mechanism for Tumor Cell Escape from PD-1/PD-L1 Inhibition.
- Published in:
- Cancers, 2019, v. 11, n. 9, p. 1318, doi. 10.3390/cancers11091318
- By:
- Publication type:
- Article
It Takes Two to Tango: Potential Prognostic Impact of Circulating TGF-Beta and PD-L1 in Pancreatic Cancer.
- Published in:
- Life (2075-1729), 2022, v. 12, n. 7, p. 960, doi. 10.3390/life12070960
- By:
- Publication type:
- Article
Biological Hallmarks and New Therapeutic Approaches for the Treatment of PDAC.
- Published in:
- Life (2075-1729), 2021, v. 11, n. 8, p. 843, doi. 10.3390/life11080843
- By:
- Publication type:
- Article
Third generation EGFR inhibitor osimertinib combined with pemetrexed or cisplatin exerts long-lasting anti-tumor effect in EGFR-mutated pre-clinical models of NSCLC.
- Published in:
- Journal of Experimental & Clinical Cancer Research (17569966), 2019, v. 38, n. 1, p. N.PAG, doi. 10.1186/s13046-019-1240-x
- By:
- Publication type:
- Article
Acquired BRAF G469A Mutation as a Resistance Mechanism to First-Line Osimertinib Treatment in NSCLC Cell Lines Harboring an EGFR Exon 19 Deletion.
- Published in:
- 2019
- By:
- Publication type:
- journal article